September 03, 2025

Vitiligo Depression Risk Varies by Race

Analysis of national health records shows vitiligo is linked to higher depression odds in certain racial and ethnic groups, highlighting variation in mental health burden across populations.

Conexiant

September 03, 2025

Study Maps Delta-Like Protein 3 and SEZ6 Across Tumor Types

Researchers highlight distinct Delta-like protein 3 and seizure-related 6 homolog patterns in neuroendocrine tumors.

Conexiant

August 28, 2025

First Generic GLP-1 for Weight Loss Approved

FDA approves Teva’s generic Saxenda (liraglutide) with adult and adolescent indications and a boxed thyroid tumor warning.

Conexiant

August 28, 2025

Girl With Waterdrop-Like Papules: What’s Your Diagnosis?

A teenager with atopic dermatitis presented with several painless, flesh-colored papules limited to the trunk. Dermoscopy and biopsy show selective loss of elastic fibers after prior molluscum contagiosum. What’s your diagnosis?

Conexiant

August 26, 2025

Are Daily Drinks Causing Hair Loss?

Comprehensive analysis reveals specific dietary interventions that significantly impact hair health, with some beverages showing harmful effects.

Conexiant

August 25, 2025

Did Politics Delay CDC Measles Response?

Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.

KFF Health News

August 22, 2025

Nemolizumab Study Tracks 68 Weeks of Relief

A long-term clinical study finds that the biologic therapy nemolizumab, when used with topical corticosteroids, continues to improve itch, sleep, and skin symptoms in prurigo nodularis patients over 68 weeks.

Conexiant

August 14, 2025

Thai Trial Tests Turmeric Emulgel Skin Safety

Thai investigators test a botanical emulgel formulation to identify early safety signals related to skin irritation and allergenicity before advancing to patient trials.

Conexiant

August 12, 2025

FDA Approves First Therapy for Non-cystic Fibrosis Bronchiectasis

Brensocatib (Brinsupri) will offer a new treatment option for patients 12 years and older.

Conexiant